

Fig. 1

250 →




Fig. 2

300




FIG. 3





Fig 4A

FIG. 4B




Fig 4B

05931304




Fig 5




Fig 6

09:00:00




Fig 7




Fig 8A





FIG. 8B

MCS: RF and Microwave



▪ Detects protein “soft vibrations”

▪ Protein Motions 10 psec – 100 nsec



▪ Complexation of Solvent

▪ Water, ions, cofactors, small molecules, other proteins



Integration of the Biology



- Biological systems as dielectric circuit element
- Integration into circuit configurations



Permittivity vs. Structure: Fibrinogen Digest


Digestion of Fibrinogen with Crude Protease

010124rgc_fib_digestion_2a.xls




Tyrosine kinase assay

.132 units/ul c-src, 200 uM (.3 mg/ml) substrate (521) and 150 uM ATP




MCS broadband signatures

Differ between proteins




Value Proposition

- Permittivity → Function
- No Engineering → Direct and Rapid Access



MCS in Drug Discovery:


A Parallel Approach




MCS: solving discovery problems





- “Target-fishing”
 - we can detect proteins in solution
 - we can classify unknown protein targets
 - we can de-orphan unknown protein targets
- Quantifying binding
- Qualifying leads using protein/ligand classification with MCS
- SAR using MCS
- Cellular assays with MCS

MCS in Drug Discovery





Similar proteins have similar signatures Change in permittivity at 1.3 GHz







Tertiary structural homology prediction

(hypothetical)









...Enabling clustering for compound effect

(hypothetical)



IL-2/IL-2R Inhibitors

- IL-2 is the principle cytokine involved in cell-mediated immunity.
- Antibodies against IL-2R α approved for graft rejection.
- Well-characterized small-molecule inhibitors of IL-2 have been discovered




$IC_{50} = 3 \mu M$



SUNESIS

Roche Research Center (Nutley)
J.W. Tilley, et al. JACS (1997) 119, 7589-7590.


MCS analysis of binding to IL-2, IL-4



MCS binding results same as others


Method	IC_{50}/K_d
SPA	3 μM
MCS	4 μM
AUC	5 μM
SPR	20 μM
ITC	4 μM

SPA – scintillation proximity assay
MCS – multipole coupling spectroscopy
AUC – analytical ultracentrifugation
SPR – surface plasmon resonance
ITC – isothermal calorimetry



MCS in Drug Discovery

Drug Discovery Process




Ligand function classification

- “Bin” hits
 - agonists would cause similar responses to each other
 - distinct responses from antagonists
- Nuclear Receptor-based
 - “binning” of hits
 - quantify relationships to known compounds
 - e.g. Ligand-1 like or Ligand-2 like


Lack of a functional readout is a problem

- No ready, quick method for categorizing the effect a "hit" chemical has on a given target, when certain profiles are desired (ie, a functional, but not chemical, copy)
- Clear desire for a fast means of "target-fishing" using annotated compound libraries and other techniques


MCS of NR – L1 interaction at 1.3 GHz



Year	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	



...Enabling clustering for ligand function *(hypothetical)*




Structure/activity using MCS ?

- The opportunity:
- Perform X-ray crystallography or NMR routinely
- Earlier in the discovery process
- The problem:
- Cost, reagents required, technology repertoire limitations, and time-consuming nature of the processes involved, are prohibitive

Protein Function: Estrogen receptor-ligand interaction

- X-ray analysis has shown that DES (agonist) and Tamoxifen (antagonist) cause subtly different conformation changes to ER on binding interaction



MCS signatures correlate interaction data




SAR Data from ER
Model System

SAR with MCS – x-ray in advance


Obtaining predicted structural readouts, enabled by “wet-lab” MCS data, and augmented by unique software...

- Jump starts SAR, typically undertaken later

...Enabling clustering for ligand function (hypothetical)



MCS in Drug Discovery



MCS: solving discovery

problems

■ "Target-fishing"

- we can detect proteins in solution
- we can classify unknown protein targets
- we can de-orphan unknown protein targets

■ Quantifying binding

- Qualifying leads using protein/ligand classification with MCS

■ SAR using MCS

■ Cellular assays with MCS

Cellular MCS: Overview

- Protein structure → cell organization
- Many physiologic processes can be measured
 - GPCR-mediated pathway induction
 - Ion channel modulation
 - Morphologic changes
 - Apoptotic events

Cellular MCS

- Protein Structure → Cellular Organisation
- MCS Measures Physiologic Changes in Cells
 - Ion Flux
 - Cytosolic cAMP/Ca²⁺
 - Morphologic Changes
 - Membrane changes

Specificity in MCS Cellular Analyses


- Spectral Response
- Kinetics
- “Orthogonal” properties
 - Protein expression levels
 - Focused libraries
 - Diverse cell populations

MCS hits major screening bottlenecks...

- Target ID, validation, *access* ✓
- Rapid Assay Development ✓
- Secondary Screening and Lead Optimization ✓
- Data Management and Analysis ✓

...and MCS meets defined “drivers” for new detection technologies


- Simple one step homogeneous assay ✓
- Avoid radioactivity, safety, disposal costs ✓
- Sensitivity to replace radioactivity ✓
- Reagent, target and compound sparing ✓
- Speed / throughput ✓
- Higher quality information ✓



A GPCR-mediated pathway:


Activation of muscarinic m₁ receptor

Gq-coupled receptor **Agonist (carbachol)**



CHO_{m1} Cell

Ca Flux 2° Assay on LjL Analyst




CPW

- 50MHz – 1GHz
- 101 points, -10 dBm
- IF Bandwidth – 10Hz
- SP11 & SP21
- Au & Pt chips
- 5×10^4 cells/well plated the day before
- Vivian's New Sucrose Buffer


Signature Bioscience, Inc.

M1 Cells on .505 Pt CPW




MCS cellular response

- CHO cells – wild type and transfected with well-known GPCR (Gq-coupled)
- Agonist stimulation is seen in transfected cells, not in WT cells
- 2ndary assay: Calcium flux measured in L_JL Analyst





Time course of response to agonist




Dose-Response Curves:

CHO-K1 vs. CHO-M1 : carbachol




PZP Dose curves ... MCS & Ca²⁺ Flux

CHO_{M1} cells treated with 300 nM Carbachol +/- Pirenzepine



300 nM Carb + PZP

CHO_{M1} cells treated with 300 nM Carbachol +/- Pirenzepine




M1 – 300 nM Carb vs PZP

Doses


Conclusions:

- PZP always blocks activation by 300 nM Carbachol
- Dose of PZP required to block Carb response varies everyday (look at 3 nM, 10 nM)
- Range of positive response can vary a lot


CHO_{M1} cells treated with 300 nM Carbachol +/- Pirenzepine




M1 - 300 nM Carbachol +/- PZP (S11, Pt. 7-13-01)



CHO_{M1} cells treated with 300 nM Carbachol +/- Pirenzepine



M1 - 300 nM Carbachol +/- PZP (7-11-01, S11, Pt)




Regeneron




Signature
BioScience, Inc.

CHO_{M1} cells treated with 300 nM Carbachol +/- Pirenzepine

CHO_{M1} cells treated with 300 nM Carbachol +/- Pirenzepine




CHO_{M1} cells treated with 300 nM Carbachol +/- Pirenzepine




Simon plot..

TZP vs PZP on M1WT3 Treated w/ 1uM Carbachol GOLD CPW S21




MCS cellular response to ionomycin

CHOwt



CHO-transfected



Thapsigargin

